Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism

Drug Metabolism and Disposition

Volumn 33, Issue 7, 2005, Pages 969-976

  Winter, Helen R ^a,b   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FLUCONAZOLE; HYDROXYLAMINE; ISOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SULFADIAZINE; SULFAPHENAZOLE; TOLBUTAMIDE;

ACETYLATION; ARTICLE; CYTOSOL; DETOXIFICATION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; MEASUREMENT; PATIENT; PRIORITY JOURNAL; SIDE EFFECT;

ANTIPROTOZOAL AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FLUCONAZOLE; HUMANS; ISOENZYMES; MICROSOMES, LIVER; OXIDATION-REDUCTION; SULFADIAZINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 22344449264     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.002998     Document Type: Article

References (33)

1. Atef M and Nielsen P (1975) Metabolism of sulfadiazine in goats. Xenobiotica 5:167-172.
2. Butcher NJ, Boukouvala S, Sim E, and Minchin RF (2002) Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomic J 2:30-42.
3. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
4. Gill HJ, Tjia JF, Kitteringham NR, Pirmohamed M, Back DJ, and Park BK (1999) The effect of genetic polymorphisms in CYP2C9 on sulfamethoxazole N-hydroxylation. Pharmacogenetics 9:43-53.
5. Grant DM, Blum M, Beer M, and Meyer UA (1991) Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184-191.
6. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, Lumholtz IB, Arroe M, Abildgaard U, and Skovsted L (1979) The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl 624:106-110.
7. Haverkos HW (1987) Assessment of therapy for toxoplasmic encephalitis. The TE study group. Am J Med 82:907-914.
8. Hickman D, Wang J-P, Wang Y, and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and the suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
9. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, and Roots I (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286-296.
10. Kunze KL, Wienkers LC, Thummel KE, and Trager WF (1996) Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 24:414-421.
11. Leone N, Barzaghi N, Monteleone M, Perucca E, Cerutti R, and Crema A (1987) Pharmacokinetics of co-trimazine after single and multiple doses. Arzneim Forsch/Drug Res 37:70-74.
12. Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG, Marche C, Vedrenne C, and Vilde JL (1988) Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Am J Med 84:94-100.
13. Levy RH (1995) Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 36 (Suppl 5):S8-S13.
14. Miners J (2002) CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response. Pharmacogenetics 12:91-92.
15. Mitra AK, Thummel KE, Kalhorn TF, Kharash ED, Unadkat JD, and Slattery JT (1995) Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 58:556-566.
16. Mitra AK, Thummel KE, Kalhorn TF, Kharash ED, Unadkat JD, and Slattery JT (1996) Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin Pharmacol Ther 59:332-340.
17. Nouws JF, Firth EC, Vree TB, and Baakman M (1987) Pharmacokinetics and renal clearance of sulfamethazine, sulfamerazine and sulfadiazine and their N4-acetyl and hydroxy metabolites in horses. Am J Vet Res 48:392-402.
18. Nouws JF, Mevius D, Vree TB, Baakman M, and Degen M (1988) Pharmacokinetics, metabolism and renal clearance of sulfadiazine, sulfamerazine and sulfamethazine and of their N4-acetyl and hydroxy metabolites in calves and cows. Am J Vet Res 49:1059-1065.
19. Palamanda JR, Hickman D, Ward A, Sim E, Romkes-Sparks M, and Unadkat JD (1995) Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with anti-opportunistic infection drugs. Drug Metab Dispos 23:473-477.
20. Rettie AE, Eddy AC, Heimark LD, Gibaldi M, and Trager WF (1989) Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 17:265-270.
21. Rieder MJ, Uetrecht J, Shear NH, and Spielberg SP (1988) Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 244:724-728.
22. Shaw PN and Houston JB (1987) Kinetics of drug metabolism inhibition: use of metabolite concentration-time profiles. J Pharmacokinet Biopharm 15:497-510.
23. Shear NH and Spielberg SP (1985) In vitro evaluation of a toxic metabolite of sulfadiazine. Can J Physiol Pharmacol 63:1370-1372.
24. Shon JH, Yoon YR, Kim KA, Lim YC, Lee KJ, Park JY, Cha IJ, Flockhart DA, and Shin JG (2002) Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12:111-119.
25. Veronese ME, Doecke CJ, MacKenzie PI, McManus ME, Miners JO, Rees DL, Gasser R, Meyer UA, and Birkett DJ (1993) Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 289:553-538.
26. Vree TB, Beneken Kolmer EW, and Peeters A (1991a) Comparison of the metabolism of four sulfonamides between humans and pigs. Vet Q 13:236-240.
27. Vree TB, Schoondermark-van de Ven E, Verwey-van Wissen CP, Bars AM, Swolfs A, van Galen PM, and Amatdjais-Groenen H (1995) Isolation identification and determination of sulfadiazine and its hydroxy metabolites and conjugates from man and rhesus monkey by highperformance liquid chromatography. J Chromatogr B Biomed 670:111-123.
28. Vree TB, Vree JB, Beneken Kolmer EW, and Hekster YA (1991b) Novel oxidative pathways of sulfapyridine and sulfadiazine by the turtle Pseudemys scripta elegans. Vet Q 13:218-224.
29. Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, and Unadkat JD (2004a) The effect of clarithromycin, fluconazole and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) Clin Pharmacol Ther 76:579-587.
30. Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, and Unadkat JD (2004b) The effect of clarithromycin, fluconazole and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283) Clin Pharmacol Ther 76:313-322.
31. Winter HR, Wang Y, and Unadkat JD (2000) CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos 28:865-868.
32. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Bonjeau JC, Beaune P, and Bagot M (1995) A slow acetylator phenotype is a risk factor for sulfonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 5:255-258.
33. Wrighton SA, Thomas PE, Willis P, Maines SL, Watkins PB, Levin W, and Guzelian PS (1987) Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. J Clin Investig 80:1017-1022.